Pharma Giants Pfizer and Celgene Strategically Expand Portfolios for Future Growth

Reese Marlowe in Health & Wellness December 2025 • 3 min read.

"Recent moves by Pfizer and Celgene highlight a renewed focus on strategic acquisitions, innovative drug development, and sustainable practices."

The pharmaceutical industry is in constant flux, driven by the need for innovation, growth, and adaptation to evolving market dynamics. Recent strategic moves by industry giants like Pfizer and Celgene illustrate these trends, with a focus on acquiring promising assets, developing innovative therapies, and embracing sustainable practices.

Pfizer, after abandoning its merger with Allergan due to unfavorable tax rule changes, is now focusing on smaller, strategic acquisitions to bolster its new product portfolio. Meanwhile, Celgene is expanding its reach through collaborations aimed at pioneering new approaches in drug development, particularly in immuno-oncology.

These developments reflect a broader industry trend towards precision medicine, sustainable manufacturing, and strategic partnerships to drive innovation and address unmet medical needs. By examining these specific cases, we can gain insights into the strategies that are shaping the future of pharmaceuticals.

Pfizer's Strategic Acquisition of Anacor Pharmaceuticals

Strategic pharmaceutical alliances symbolized by interconnected molecules.

In a significant move to strengthen its dermatology pipeline, Pfizer has acquired Anacor Pharmaceuticals for approximately $5.2 billion. Anacor, a biotech firm specializing in boron-containing small-molecule therapeutics, brings to Pfizer a promising treatment for eczema, crisaborole, which is currently under FDA review.

Crisaborole, a topical treatment for eczema, has the potential to generate peak annual sales of $2 billion or more, according to Pfizer. This optimism is based on the fact that a novel eczema treatment has not been approved in over 15 years, highlighting the significant unmet need in this therapeutic area.

Novel Mechanism: Crisaborole leverages boron's unique ability to form coordinate covalent bonds, enhancing drug-target interaction.
Strategic Fit: The acquisition aligns with Pfizer's strategy to focus on innovative, patent-protected products after its failed attempt to merge with Allergan.
Market Potential: With a potential $2 billion in peak annual sales, crisaborole could become a key growth driver for Pfizer's dermatology franchise.

Founded in 2002, Anacor has focused on leveraging boron's unique chemical properties to create novel therapeutics. For Pfizer, this acquisition represents a strategic shift towards smaller, more targeted deals aimed at quickly enhancing its product offerings and market position. This approach allows Pfizer to remain agile and responsive to market opportunities without the complexities and risks associated with large-scale mergers.

Looking Ahead: Strategic Imperatives for Pharma

The moves by Pfizer and Celgene underscore critical strategic imperatives for pharmaceutical companies in today's dynamic environment. These include a focus on targeted acquisitions, innovative drug development, and sustainable practices. By embracing these strategies, companies can position themselves for long-term success and contribute to the advancement of healthcare.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What was the primary motivation behind Pfizer's acquisition of Anacor Pharmaceuticals?

Pfizer's primary motivation for acquiring Anacor Pharmaceuticals was to bolster its dermatology pipeline with crisaborole, a promising treatment for eczema. This acquisition reflects Pfizer's strategic shift towards smaller, more targeted deals following the abandonment of its merger with Allergan. Crisaborole, with its novel mechanism and potential for significant sales, offered Pfizer a rapid way to enhance its product offerings and market position, aligning with its focus on innovative, patent-protected products.

How does crisaborole work, and why is it considered a significant advancement in eczema treatment?

Crisaborole is a topical treatment for eczema that leverages boron's unique ability to form coordinate covalent bonds, enhancing drug-target interaction. This novel mechanism sets it apart from existing treatments. Crisaborole's significance lies in the fact that no new eczema treatment has been approved in over 15 years, indicating a significant unmet medical need. With the potential to generate peak annual sales of $2 billion or more, crisaborole could become a key growth driver for Pfizer's dermatology franchise, offering a much-needed solution for patients.

What strategic imperatives are highlighted by the actions of Pfizer and Celgene in the pharmaceutical industry?

The actions of Pfizer and Celgene highlight critical strategic imperatives for pharmaceutical companies. These include a focus on targeted acquisitions, innovative drug development, and sustainable practices. Pfizer's acquisition of Anacor exemplifies targeted acquisitions, while Celgene's collaborations for drug development demonstrate a commitment to innovation. Both companies' moves reflect a broader industry trend towards precision medicine, sustainable manufacturing, and strategic partnerships to drive innovation and address unmet medical needs, positioning them for long-term success.

Why did Pfizer opt for smaller, strategic acquisitions like Anacor instead of pursuing large-scale mergers like the one with Allergan?

Pfizer shifted its strategy towards smaller, strategic acquisitions after abandoning its merger with Allergan due to unfavorable tax rule changes. This new approach allows Pfizer to remain agile and responsive to market opportunities without the complexities and risks associated with large-scale mergers. The acquisition of Anacor, for instance, allowed Pfizer to quickly enhance its product offerings with a promising treatment like crisaborole, reflecting a strategic focus on innovation and patent-protected products to drive growth.

How are Celgene's collaborations contributing to innovation in the pharmaceutical landscape, and what area of drug development is it particularly focused on?

Celgene is expanding its reach through collaborations, aiming at pioneering new approaches in drug development, particularly in immuno-oncology. Although the specific details of Celgene's collaborations are not fully detailed, the general trend highlights the importance of strategic partnerships in driving innovation. These collaborations enable Celgene to explore new avenues and technologies, contributing to advancements in precision medicine and addressing unmet medical needs. Such partnerships allow for shared expertise and resources, accelerating the development of innovative therapies in areas like immuno-oncology.